It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
In the gut ecosystem, microorganisms regulate group behaviour and interplay with the host via a molecular system called quorum sensing (QS). The QS molecule 3-oxo-C12:2-HSL, first identified in human gut microbiota, exerts anti-inflammatory effects and could play a role in inflammatory bowel diseases where dysbiosis has been described. Our aim was to identify which signalling pathways are involved in this effect. We observed that 3-oxo-C12:2-HSL decreases expression of pro-inflammatory cytokines such as Interleukine-1β (− 35%) and Tumor Necrosis Factor-α (TNFα) (− 40%) by stimulated immune RAW264.7 cells and decreased TNF secretion by stimulated PBMC in a dose-dependent manner, between 25 to 100 µM. Transcriptomic analysis of RAW264.7 cells exposed to 3-oxo-C12:2-HSL, in a pro-inflammatory context, highlighted JAK-STAT, NF-κB and TFN signalling pathways and we confirmed that 3-oxo-C12:2-HSL inhibited JAK1 and STAT1 phosphorylation. We also showed through a screening assay that 3-oxo-C12:2-HSL interacted with several human bitter taste receptors. Its anti-inflammatory effect involved TAS2R38 as shown by pharmacologic inhibition and led to an increase in intracellular calcium levels. We thus unravelled the involvement of several cellular pathways in the anti-inflammatory effects exerted by the QS molecule 3-oxo-C12:2-HSL.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France (GRID:grid.465261.2) (ISNI:0000 0004 1793 5929); Paris Center for Microbiome Medicine (PaCeMM) FHU, APHP, Paris, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109)
2 Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France (GRID:grid.465261.2) (ISNI:0000 0004 1793 5929); Paris Center for Microbiome Medicine (PaCeMM) FHU, APHP, Paris, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109); PSL University, EPHE, Paris, France (GRID:grid.440907.e) (ISNI:0000 0004 1784 3645)
3 University of Bourgogne Franche-Comté, Centre des Sciences du Goût et de l’Alimentation, UMR 1324 INRAE, UMR 6265 CNRS, Dijon, France (GRID:grid.493090.7) (ISNI:0000 0004 4910 6615)
4 Parean Biotechnologies, Saint Malo, France (GRID:grid.50550.35)
5 LVMH Recherche, Life Science Department, Saint Jean de Braye, France (GRID:grid.480251.a) (ISNI:0000 0001 0276 1637)
6 Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France (GRID:grid.465261.2) (ISNI:0000 0004 1793 5929); Paris Center for Microbiome Medicine (PaCeMM) FHU, APHP, Paris, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109); Sorbonne Université, Département de Gastroentérologie et Nutrition, APHP, Hôpital Saint-Antoine, Paris, France (GRID:grid.462844.8) (ISNI:0000 0001 2308 1657)